Charles Morris joined Prelude in 2026 as Chief Medical Officer. He is a medical oncologist with more than 30 years of oncology drug development experience in the biotech and pharmaceutical industry.  Prior to joining Prelude, he was CMO of LAVA Therapeutics until its acquisition by Xoma Royalty in 2025. In other CMO roles with Celyad Oncology, Radius Health, PsiOxus Therapeutics, ImmunoGen and Allos Therapeutics, Dr. Morris contributed to all phases of development for several novel programs targeting solid and hematological tumor indications, including ELAHERE® (mirvetuximab soravtansine) for ovarian cancer and ONSERDU® (elacestrant) for breast cancer. He previously served as vice president of worldwide clinical research at Cephalon where he supported the approval of TREANDA® (bendamustine) for the treatment of indolent non-Hodgkin lymphoma and chronic lymphocytopenia. Dr. Morris began his career at AstraZeneca where he held roles of increasing responsibility including global medical lead for Faslodex® (fulvestrant) through its approval for breast cancer. He received his medical degrees and a Bachelor of Medical Science in Clinical Pharmacology and Therapeutics from Sheffield University Medical School and is a member of the Royal College of Physicians of London.